OBJECTIVES: To assess the long-term compliance with repeated injections of intravesical botulinum toxin (BT) in a 'real-life' mixed population of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity. To identify the reasons why patients discontinued BT therapy and to explore the outcomes of those patients who did discontinue treatment. PATIENTS AND METHODS: Retrospective evaluation of the case notes of a series of patients who had received intravesical BT treatment at a large UK teaching hospital. No antibiotic prophylaxis was given for the procedure. RESULTS: Over a period of 7 years, 268 patients were initiated on intravesical BT treatment for overactive bladder (OAB) at our institution, with 137 followed up for ≥36 months, with 80 patients having ≥60 months follow-up after their first injection. Almost two-thirds of patients (61.3%) had discontinued intravesical BT therapy at 36 months, with a 63.8% discontinuation rate at 60 months. The main reasons for discontinuation were tolerability issues, mainly urinary tract infections and the need for clean intermittent self-catheterisation. Primary and secondary losses of efficacy were of secondary importance. Most of the patients that discontinued have remained under urology care and now receive alternative methods of treatment. CONCLUSIONS: Intravesical BT therapy is an effective short-term treatment for OAB. With time, two-thirds of patients discontinued treatment usually because of the tolerability issues associated with treatment.
OBJECTIVES: To assess the long-term compliance with repeated injections of intravesical botulinum toxin (BT) in a 'real-life' mixed population of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity. To identify the reasons why patients discontinued BT therapy and to explore the outcomes of those patients who did discontinue treatment. PATIENTS AND METHODS: Retrospective evaluation of the case notes of a series of patients who had received intravesical BT treatment at a large UK teaching hospital. No antibiotic prophylaxis was given for the procedure. RESULTS: Over a period of 7 years, 268 patients were initiated on intravesical BT treatment for overactive bladder (OAB) at our institution, with 137 followed up for ≥36 months, with 80 patients having ≥60 months follow-up after their first injection. Almost two-thirds of patients (61.3%) had discontinued intravesical BT therapy at 36 months, with a 63.8% discontinuation rate at 60 months. The main reasons for discontinuation were tolerability issues, mainly urinary tract infections and the need for clean intermittent self-catheterisation. Primary and secondary losses of efficacy were of secondary importance. Most of the patients that discontinued have remained under urology care and now receive alternative methods of treatment. CONCLUSIONS: Intravesical BT therapy is an effective short-term treatment for OAB. With time, two-thirds of patients discontinued treatment usually because of the tolerability issues associated with treatment.
Authors: Maria Paola Bertapelle; Mario Vottero; Giulio Del Popolo; Marco Mencarini; Edoardo Ostardo; Michele Spinelli; Antonella Giannantoni; Anna D'Ausilio Journal: World J Urol Date: 2014-09-14 Impact factor: 4.226